✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Clinical Reference

Mechanism of Action

Released: Last reviewed:

Semaglutide selectively activates the GLP-1 receptor: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, reduced caloric intake. Half-life ~7 days.

Clinical reference
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Overview

Semaglutide selectively activates the GLP-1 receptor: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, reduced caloric intake. Half-life ~7 days.

Related clinical pages

Key facts, checked November 20, 2026

The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence homology to human GLP-1 that binds to and activates the GLP-1 receptor. GLP-1 regulates appetite and caloric intake, and the receptor is present in brain areas involved in appetite; in animal studies semaglutide reached and activated neurons in those regions. The label says the exact mechanism of its cardiovascular benefit has not been established. Semaglutide also delays gastric emptying, which is why oral medicines taken at the same time may be absorbed differently.